Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New pill could ease rheumatoid arthritis pain

NCT ID NCT05848258

Disease control Sponsor: Eli Lilly and Company Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested an experimental oral drug called LY3871801 in 164 adults with moderately-to-severe rheumatoid arthritis. The goal was to see if it reduces joint swelling and pain better than a placebo. The trial is complete, and results will help decide if further testing is warranted.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
LY3871801 (oral drug)
What this could lead to
If successful, this could provide a new oral treatment option to control rheumatoid arthritis symptoms and reduce disease activity.
What could go wrong
This is an early phase 2 trial with only 164 participants, so results may not apply to everyone. The drug may not work better than placebo or could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

164 people

The number who actually took part.

Started

May 2023

Finished

Apr 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Have a diagnosis of adult-onset RA for at least 3 months prior to screening as defined by the 2010 ACR/European League Against Rheumatism (EULAR) classification criteria. * Have moderately-to-severely active RA at screening and baseline, defined by the presence of * ≥6 swollen joints based on 66 joint count, and * ≥6 tender joints based on 68 joint count. * Have had a history of failure (an inadequate response, intolerance, or loss of response) to at least 1 conventional synthetic disease modifying anti rheumatic drug (csDMARD) and either 1 biologic (bDMARD), or targeted synthetic (tsDMARD) treatment. Exclusion Criteria: * Have Class IV RA according to ACR revised criteria * Have presence of 1 or more significant concurrent medical conditions per investigator judgment, including but not limited to * poorly controlled diabetes or hypertension * chronic kidney disease stage IIIa or IIIb, IV, or V * symptomatic heart failure according to New York Heart Association class II, III, or IV * myocardial infarction,unstable angina pectoris, stroke, or transient ischemic attack within the past 12 months before randomization * severe chronic pulmonary disease, for example, requiring oxygen therapy * major chronic inflammatory disease or connective tissue disease other than RA, including but not limited to * systemic lupus erythematosus * psoriatic arthritis * axial spondyloarthritis,including ankylosing spondylitis and non-radiographic axial spondyloarthritis * reactive arthritis * gout * scleroderma * polymyositis * dermatomyositis * active fibromyalgia, or * multiple sclerosis

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Rheumatoid arthritis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

rheumatoid arthritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Rheumatoid arthritis

Contacts and locations

Locations

  • Accellacare - Salisbury

    Salisbury, North Carolina, 28144, United States

  • Accurate Clinical Research, Inc

    Lake Charles, Louisiana, 70605, United States

  • Accurate Clinical Research, Inc

    Houston, Texas, 77089, United States

  • Advanced Clinical Research of Orlando - Ocoee

    Ocoee, Florida, 34761, United States

  • All India Institute of Medical Sciences (AIIMS) - Nagpur

    Nagpur, 441108, India

  • Avron Hospitals

    Ahmedabad, 380013, India

  • Biológicos Especializados

    Mexico City, 06700, Mexico

  • CENUDIAB

    Buenos Aires, C1440AAD, Argentina

  • CHD Vendee

    La Roche-sur-Yon, 85000, France

  • CHU Montpellier Lapeyronie Hospital

    Montpellier, 34295, France

  • CHU Strasbourg-Hautepierre

    Strasbourg, 67098, France

  • CHU de Nice

    Nice, 06000, France

  • CIMAB SA de CV

    Torreón, 27000, Mexico

  • CIPREC

    Buenos Aires, C1061AAS, Argentina

  • CRU Hungary Kft.

    Encs, 3860, Hungary

  • Centre Hospitalier Regional D'Orleans

    Orléans, 45067, France

  • Centre Hospitalier Universitaire de Reims - l'Hôpital Maison Blanche

    Reims, 51092, France

  • Centro de Atención e Investigación Cardiovascular del Potosí

    San Luis Potosí City, 78200, Mexico

  • Centrum Medyczne Reuma Park

    Warsaw, 02-665, Poland

  • Cicmex Centro de Investigación Clínica de México

    Morelia, 58020, Mexico

  • Conquest Research

    Winter Park, Florida, 32789, United States

  • Encore Medical Research - Weston

    Weston, Florida, 33331, United States

  • Grant Medical Foundation - Ruby Hall Clinic

    Pune, 411001, India

  • HRF II - Hamburger Rheuma Forschungszentrum II MVZ für Rheumatologie und Autoimmunmedizin Hamburg GmbH / -T

    Hamburg, 20095, Germany

  • Hopitaux Universitaires Paris Centre-Hopital Cochin

    Paris, 75679, France

  • Hospital Aranda de La Parra

    León, 37000, Mexico

  • Hospital Universitario "Dr. Jose Eleuterio Gonzalez"

    Monterrey, 66460, Mexico

  • Hull Royal Infirmary

    Hull, HU3 2JZ, United Kingdom

  • Icahn School of Medicine at Mount Sinai

    New York, New York, 10029, United States

  • Instituto de Alta Complejidad San Isidro

    San Isidro, 1642, Argentina

  • Integrity Clinical Research

    Doral, Florida, 33122, United States

  • Investigacion y Biomedicina de Chihuahua

    Chihuahua City, 31000, Mexico

  • Joseph S. and Diane H. Steinberg Ambulatory Care Center

    Brooklyn, New York, 11201, United States

  • Kistarcsai Flor Ferenc Korhaz

    Kistarcsa, 2143, Hungary

  • Kohler and Milstein Research S.A. de C.V.

    Mérida, 97070, Mexico

  • MICS Centrum Medyczne Warszawa

    Warsaw, 00-874, Poland

  • Mautalen Salud e Investigación

    Buenos Aires, C1128AAF, Argentina

  • Medical Care and Research SA de CV

    Mérida, 97070, Mexico

  • Medical Plus

    Uherské Hradiště, 686 01, Czechia

  • Medicina Reumatológica

    San Fernando, 1646, Argentina

  • Medipoint Hospitals Pvt. Ltd.

    Pune, 411007, India

  • New Cross Hospital

    Wolverhampton, WV10 0QP, United Kingdom

  • Newport Huntington Medical Group

    Huntington Beach, California, 92648, United States

  • Nova Reuma Domyslawska i Rusilowicz Spolka Partnerska Lekarza Reumatologa i Fizjoterapeuty

    Bialystok, 15-707, Poland

  • Nzoz Bif-Med

    Bytom, 41-902, Poland

  • Overlake Arthritis and Osteoporosis Center

    Bellevue, Washington, 98004, United States

  • Regia Med Kft

    Székesfehérvár, 8000, Hungary

  • Revita Clinic

    Budapest, 1027, Hungary

  • Sushruta Multispeciality Hospital & Research Centre

    Hubli, 580021, India

  • Universitaetsklinikum Koeln

    Cologne, 50937, Germany

  • Vital Medical Center

    Veszprém, 8200, Hungary

  • Vásárhelyi Sárkányfű KFT

    Hódmezővásárhely, 6800, Hungary

  • Willow Rheumatology and Wellness PLLC

    Willowbrook, Illinois, 60527, United States

  • Óbudai Egészségügyi Centrum

    Budapest, 1036, Hungary

More trials for these conditions

Other studies related to the condition(s) this trial covers.